We read with interest the article by Frederiksen et al about the increased risk of developing hematologic and nonhematologic cancers in a large cohort of Danish patients with myeloproliferative neoplasms (MPNs).1 In a previous study2 we reported that MPN patients have a 3.44-fold higher risk of lymphoid neoplasms compared with the general population, in line with current1 and other results.3 Considering nonhematologic cancers, Frederiksen et al reported a standardized incidence ratio (SIR) value of 1.2 (95% CI: 1.0-1.4) for essential thrombocythemia (ET) and 1.4 (95% CI: 1.3-1.5) for polycythemia vera (PV).1 These estimates were based on 1578 ET and 4625 PV patients after a median follow-up of 4.0 and 5.0 years, respectively.
展开▼
